CU20200064A7 - Expresión de la proteína de superficie neumocócica a (pspa) - Google Patents

Expresión de la proteína de superficie neumocócica a (pspa)

Info

Publication number
CU20200064A7
CU20200064A7 CU2020000064A CU20200064A CU20200064A7 CU 20200064 A7 CU20200064 A7 CU 20200064A7 CU 2020000064 A CU2020000064 A CU 2020000064A CU 20200064 A CU20200064 A CU 20200064A CU 20200064 A7 CU20200064 A7 CU 20200064A7
Authority
CU
Cuba
Prior art keywords
expression
pspa
surface protein
pneumococcal surface
discloses
Prior art date
Application number
CU2020000064A
Other languages
English (en)
Other versions
CU24709B1 (es
Inventor
Mahima Datla
Swetha Kamireddy
Narender Dev Mantena
Ramesh Venkat Matur
Rajan Sriraman
Original Assignee
Biological E Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biological E Ltd filed Critical Biological E Ltd
Publication of CU20200064A7 publication Critical patent/CU20200064A7/es
Publication of CU24709B1 publication Critical patent/CU24709B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>La presente invención se refiere a una expresión de la proteína de superficie neumocócica A (PspA). La invención representa un avance en el campo de la ingeniería genética y la tecnología de vacunas. La invención divulga vectores de expresión y células huésped recombinantes para la expresión del péptido de PspA truncada. La invención también divulga composiciones de vacunas que comprenden los péptidos truncados como proteínas transportadoras.</p>
CU2020000064A 2018-03-01 2019-03-01 Ácido nucleico que codifica la proteína de superficie neumocócica a1 (pspa1) truncada, constructo de expresión para la expresión de alto nivel de la misma y vacuna conjugada neumocócica CU24709B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841007814 2018-03-01
PCT/IB2019/051655 WO2019167008A1 (en) 2018-03-01 2019-03-01 Expression of pneumococcal surface protein a (pspa)

Publications (2)

Publication Number Publication Date
CU20200064A7 true CU20200064A7 (es) 2021-04-07
CU24709B1 CU24709B1 (es) 2024-06-11

Family

ID=66440079

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000064A CU24709B1 (es) 2018-03-01 2019-03-01 Ácido nucleico que codifica la proteína de superficie neumocócica a1 (pspa1) truncada, constructo de expresión para la expresión de alto nivel de la misma y vacuna conjugada neumocócica

Country Status (18)

Country Link
US (2) US11725029B2 (es)
EP (1) EP3758746A1 (es)
JP (2) JP7334176B2 (es)
KR (1) KR20200129121A (es)
CN (1) CN112118865A (es)
AU (1) AU2019226487A1 (es)
BR (1) BR112020017431A2 (es)
CA (1) CA3091583A1 (es)
CL (1) CL2020002246A1 (es)
CU (1) CU24709B1 (es)
EA (1) EA202092065A1 (es)
IL (1) IL277023A (es)
MX (1) MX2020009049A (es)
PH (1) PH12020551357A1 (es)
SA (1) SA520420041B1 (es)
SG (1) SG11202008124XA (es)
WO (1) WO2019167008A1 (es)
ZA (1) ZA202005414B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476929A (en) * 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
EP2434015B1 (en) * 2004-09-09 2013-11-20 Research Institute Of Innovative Technology For The Earth DNA fragment having promoter function
CA2729545C (en) 2008-06-25 2019-07-09 Vaxiion Therapeutics, Inc. Regulated genetic suicide mechanism compositions and methods
WO2010141312A2 (en) * 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN107674118A (zh) * 2016-08-02 2018-02-09 中国食品药品检定研究院 重组蛋白PspA1、PspA2和PspA3以及包含其的多糖结合疫苗

Also Published As

Publication number Publication date
JP7334176B2 (ja) 2023-08-28
CL2020002246A1 (es) 2021-01-15
SG11202008124XA (en) 2020-09-29
US11725029B2 (en) 2023-08-15
JP2021516050A (ja) 2021-07-01
JP2023154063A (ja) 2023-10-18
KR20200129121A (ko) 2020-11-17
US20230322871A1 (en) 2023-10-12
CU24709B1 (es) 2024-06-11
US20210009641A1 (en) 2021-01-14
BR112020017431A2 (pt) 2021-01-19
EP3758746A1 (en) 2021-01-06
PH12020551357A1 (en) 2021-08-23
SA520420041B1 (ar) 2024-03-14
EA202092065A1 (ru) 2020-11-19
CA3091583A1 (en) 2019-09-06
MX2020009049A (es) 2020-10-12
CN112118865A (zh) 2020-12-22
AU2019226487A1 (en) 2020-09-10
IL277023A (en) 2020-10-29
WO2019167008A1 (en) 2019-09-06
ZA202005414B (en) 2022-02-23

Similar Documents

Publication Publication Date Title
CL2018000124A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
PE20181275A1 (es) Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo
PE20181923A1 (es) Neoantigenos y metodos de su uso
PE20180505A1 (es) Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
UA120917C2 (uk) Химерний білок фактора viii та його застосування
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
MX2022015079A (es) Variantes de hsd17b13 y usos de las mismas.
CO7051009A2 (es) Composiciones del factor viii y métodos para hacerlas y usarlas
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
AR110502A1 (es) Polinucleótidos y polipéptidos de adenovirus
UY35397A (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
EA201991409A2 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
ECSP17075380A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
CL2020002246A1 (es) Expresión de proteína de superficie a neumocócica (pspa)
EA201791918A1 (ru) Модификация белков клеток-хозяев
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
CO2023003453A2 (es) Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados
CL2021001251A1 (es) Plataformas, productos y métodos para la expresión en endosporas
PE20180162A1 (es) Polipeptidos dirigidos a la fusion de vih
CO2018001339A2 (es) Sistema vector de adenovirus aviar 9 (fadv-9) y métodos asociados
EA201790241A1 (ru) Эффективная селективность в отношении рекомбинантных белков